Background This study aimed to evaluate the efficacy of once-daily liraglutide as an add-on to oral antidiabetics (OADs) on glycemic control and body weight in obese patients with inadequately controlled type 2 diabetes (T2D). Methods A total of 27 obese T2D patients who received 7 months (0.6 mg/day for the first month, 1.2 mg/day for 3 months, and 1.8 mg/day for 3 months) of liraglutide treatment as an add-on to OADs were included. Data on body weight (kg), fasting plasma glucose (FPG, mg/dL), postprandial glucose (PPG, mg/dL), and HbA1c (%), were recorded. Results Liraglutide doses of 1.2 mg/day and 1.8 mg/day were associated with significant decreases in body weight (by 8.0% and 11.9%, respectively, p < 0.01 for each) and HbA1c (by 20.0 and 26.5%, respectively, p < 0.01), while all liraglutide doses yielded significant reductions in FPG (p ranging from < 0.001 to < 0.01) and PPG (p ranging from < 0.001 to < 0.01). Glycemic parameters showed a significant reduction from the 1.2 mg/day dose to the 1.8 mg/day dose (p < 0.01 for each), whereas no further reduction in body weight was noted. Conclusion Our findings indicate favorable efficacy of liraglutide as an add-on to OADs in weight reduction and improving glycemic parameters in obese patients with inadequately controlled T2D. Once-daily liraglutide treatment was associated with significant weight loss and improved HbA1c levels only at 1.2-mg and 1.8-mg doses, while a 1.8-mg dose compared with a 1.2-mg dose seemed to enable a further improvement in glycemic control but not in weight loss.
(100)
(96)
ان السبب الرئيسي لاختيار الموضوع كونه من الاساليب الادارية الحديثة التي تهدف الى انجاح المنظمة او الشركة المبحوثة, اذ تمثلت مشكلة البحث في ما دور الادارة بالرؤية المشتركة في تعزيز التسويق الابداعي بالشركة المبحوثة, يهدف البحث الى تسليط الضوء على مفهوم الادارة بالرؤية المشتركة وانعكاساتها على التسويق الابداعي للمنظمة ، باعتبارها منهج اداري حديث يسهم في تغيير وتجديد وتطوير واقع المنظمة المبحوثة( الشرك
... Show More
The comparison of double informative priors which are assumed for the reliability function of Pareto type I distribution. To estimate the reliability function of Pareto type I distribution by using Bayes estimation, will be used two different kind of information in the Bayes estimation; two different priors have been selected for the parameter of Pareto type I distribution . Assuming distribution of three double prior’s chi- gamma squared distribution, gamma - erlang distribution, and erlang- exponential distribution as double priors. The results of the derivaties of these estimators under the squared error loss function with two different double priors. Using the simulation technique, to compare the performance for
... Show More